$BSGM
BioSig Technologies, Inc.

2023 Q3 Form 10-Q Financial Statement

#000118518523000845 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $1.000K $0.00 $8.000K
YoY Change -99.26% -100.0% -96.14%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $1.000K $8.000K
YoY Change -99.05% -94.48%
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin $2.820M $9.107M $4.302M
YoY Change -40.93% 111.69% -33.61%
% of Gross Profit 282000.0% 53775.0%
Research & Development $1.100M $1.700M $1.400M
YoY Change -35.29% 21.43% -17.65%
% of Gross Profit 110000.0% 17500.0%
Depreciation & Amortization $92.00K $92.00K $71.00K
YoY Change 9.52% 29.58% 44.9%
% of Gross Profit 9200.0% 887.5%
Operating Expenses $4.052M $10.91M $5.724M
YoY Change -38.52% 90.57% -30.16%
Operating Profit -$4.051M -$10.91M -$5.716M
YoY Change -37.54% 90.83% -29.0%
Interest Expense $0.00 $3.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$225.0K $0.00
YoY Change
Pretax Income -$4.050M -$11.13M -$5.716M
YoY Change -37.55% 94.72% -29.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.567M -$11.09M -$5.759M
YoY Change -28.33% 92.62% -25.22%
Net Earnings / Revenue -456700.0% -71987.5%
Basic Earnings Per Share -$0.06 -$1.58
Diluted Earnings Per Share -$0.06 -$0.16 -$144.6K
COMMON SHARES
Basic Shares Outstanding 74.93M shares 70.49M shares
Diluted Shares Outstanding 75.37M shares 7.028M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $490.0K $1.354M $5.077M
YoY Change -47.71% -73.33% -67.25%
Cash & Equivalents $400.0K $1.300M $5.100M
Short-Term Investments $100.0K $102.0K
Other Short-Term Assets $330.0K $423.0K $633.0K
YoY Change -27.63% -33.18% 22.91%
Inventory $219.0K $189.0K $2.026M
Prepaid Expenses $322.0K $418.0K $633.0K
Receivables $14.00K $21.00K
Other Receivables $0.00 $5.000K
Total Short-Term Assets $1.051M $1.987M $7.736M
YoY Change -65.98% -74.31% -54.36%
LONG-TERM ASSETS
Property, Plant & Equipment $593.0K $621.0K $596.0K
YoY Change -13.43% 4.19% -6.88%
Goodwill
YoY Change
Intangibles $1.000K $1.000K $1.000K
YoY Change 99900.0% 0.0%
Long-Term Investments $40.00K $69.00K
YoY Change -39.39%
Other Assets $687.0K $514.0K $42.00K
YoY Change 1461.36% 1123.81% -58.42%
Total Long-Term Assets $2.103M $2.063M $1.854M
YoY Change 9.19% 11.27% 71.99%
TOTAL ASSETS
Total Short-Term Assets $1.051M $1.987M $7.736M
Total Long-Term Assets $2.103M $2.063M $1.854M
Total Assets $3.154M $4.050M $9.590M
YoY Change -37.11% -57.77% -46.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.810M $3.236M $1.792M
YoY Change 56.28% 80.58% -45.27%
Deferred Revenue $4.000K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.911M $3.332M $1.899M
YoY Change 53.98% 75.46% -43.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $190.0K $282.0K $609.0K
YoY Change -64.55% -53.69% 2668.18%
Total Long-Term Liabilities $193.0K $282.0K $609.0K
YoY Change -63.99% -53.69% 2668.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.911M $3.332M $1.899M
Total Long-Term Liabilities $193.0K $282.0K $609.0K
Total Liabilities $4.104M $3.614M $2.508M
YoY Change 33.42% 44.1% -33.63%
SHAREHOLDERS EQUITY
Retained Earnings -$239.0M -$234.4M -$202.6M
YoY Change 14.33% 15.67%
Common Stock $79.00K $73.00K $45.00K
YoY Change 71.74% 62.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.160M $242.0K $6.857M
YoY Change
Total Liabilities & Shareholders Equity $3.154M $4.050M $9.590M
YoY Change -37.11% -57.77% -46.8%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$4.567M -$11.09M -$5.759M
YoY Change -28.33% 92.62% -25.22%
Depreciation, Depletion And Amortization $92.00K $92.00K $71.00K
YoY Change 9.52% 29.58% 44.9%
Cash From Operating Activities -$3.830M -$4.895M -$6.703M
YoY Change -22.58% -26.97% -3.14%
INVESTING ACTIVITIES
Capital Expenditures $60.00K $77.00K -$5.000K
YoY Change -220.0% -1640.0% -90.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$60.00K -$77.00K -$5.000K
YoY Change 20.0% 1440.0% -90.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.030M 4.812M 3.120M
YoY Change 275.46% 54.23% -156100.0%
NET CHANGE
Cash From Operating Activities -3.830M -4.895M -6.703M
Cash From Investing Activities -60.00K -77.00K -5.000K
Cash From Financing Activities 3.030M 4.812M 3.120M
Net Change In Cash -860.0K -160.0K -3.588M
YoY Change -79.47% -95.54% -48.55%
FREE CASH FLOW
Cash From Operating Activities -$3.830M -$4.895M -$6.703M
Capital Expenditures $60.00K $77.00K -$5.000K
Free Cash Flow -$3.890M -$4.972M -$6.698M
YoY Change -20.56% -25.77% -2.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38659
dei Entity Registrant Name
EntityRegistrantName
BIOSIG TECHNOLOGIES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4333375
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Greens Farms Road, 1st Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Westport
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06880
dei City Area Code
CityAreaCode
(203)
dei Local Phone Number
LocalPhoneNumber
409-5444
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BSGM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74927499 shares
CY2023Q2 us-gaap Cash
Cash
1252000 usd
CY2022Q4 us-gaap Cash
Cash
357000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000 usd
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
5000 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
189000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2023Q2 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
102000 usd
CY2022Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
101000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
418000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
325000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
1987000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1128000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
621000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
561000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
69000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
120000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
298000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
307000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
514000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44000 usd
CY2023Q2 us-gaap Assets
Assets
4050000 usd
CY2022Q4 us-gaap Assets
Assets
4110000 usd
CY2023Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
0 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
120000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2906000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
96000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
91000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
330000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3332000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3261000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
282000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
282000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
452000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3614000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3713000 usd
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2023Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73457375 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73457375 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54610638 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
73000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
55000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
234568000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
216232000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234399000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215974000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
242000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
313000 usd
CY2023Q2 us-gaap Minority Interest
MinorityInterest
89000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4050000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4110000 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
8000 usd
us-gaap Revenues
Revenues
5000 usd
us-gaap Revenues
Revenues
16000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1709000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1351000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2771000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2968000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9107000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4302000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15352000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10703000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
71000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10908000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5724000 usd
us-gaap Operating Expenses
OperatingExpenses
18299000 usd
us-gaap Operating Expenses
OperatingExpenses
13797000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10908000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5716000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18294000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13781000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-225000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-225000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11130000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5716000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18512000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13781000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11130000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-5716000 usd
us-gaap Profit Loss
ProfitLoss
-18512000 usd
us-gaap Profit Loss
ProfitLoss
-13781000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-37000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
43000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-59000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11093000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5759000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18425000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13722000 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
5000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
5000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
108000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
108000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11096000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5870000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18430000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13835000 usd
CY2023Q2 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.16
CY2022Q2 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.15
bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.28
bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.36
CY2023Q2 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
70281555 shares
CY2022Q2 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
39823034 shares
bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
65878496 shares
bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
37920734 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1097000 usd
CY2023Q1 bsgm Stock Value Issued In Settlement Of Debt
StockValueIssuedInSettlementOfDebt
105000 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
482000 usd
CY2023Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
6748000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1052000 usd
CY2023Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4811000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
201000 usd
CY2023Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
3245000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1567000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-69000 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11130000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12460000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1601000 usd
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
15000 usd
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000 usd
CY2022Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
3002000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-8065000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9410000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
483000 usd
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
438000 usd
CY2022Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
2818000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-317000 usd
CY2022Q2 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
108000 usd
CY2022Q2 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
-108000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-5716000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6977000 usd
us-gaap Profit Loss
ProfitLoss
-18512000 usd
us-gaap Profit Loss
ProfitLoss
-13781000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
144000 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
166000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1307000 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6891000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2166000 usd
us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
0 usd
us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
-15000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-50000 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
145000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
564000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
277000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
159000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-731000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-153000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-167000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10543000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12644000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9993000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5820000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
302000 usd
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
1567000 usd
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11560000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6122000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
895000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6582000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11659000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1252000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5077000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
105000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
5000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
5000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
108000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
502000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1300000 usd
CY2023Q2 bsgm Working Capital Deficit
WorkingCapitalDeficit
-1300000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p>
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
2 pure
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30Y
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
5000 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentrations of Credit Risk</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At June 30, 2023 and December 31, 2022, deposits in excess of FDIC limits were $0.7 million and $0.05 million, respectively.</p>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
700000 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
50000.00 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
18000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
3000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
32000 usd
us-gaap Lease Cost
LeaseCost
185000 usd
us-gaap Lease Cost
LeaseCost
216000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1496000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1477000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1307000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
189000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1477000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
189000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1307000 usd
CY2023Q2 us-gaap Deposit Assets
DepositAssets
470000 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
0 usd
CY2023Q2 us-gaap Security Deposit
SecurityDeposit
43000 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
43000 usd
CY2023Q2 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2022Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
514000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
44000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1700000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2800000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1400000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4333 usd
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16571705 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9041381 shares
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4752 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
9603 usd
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4752 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
9503 usd
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q3 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2023Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
3000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1388000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1266000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
767000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
601000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
621000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
86680 usd
us-gaap Depreciation
Depreciation
166148 usd
CY2022Q2 us-gaap Depreciation
Depreciation
66243 usd
us-gaap Depreciation
Depreciation
116625 usd
bsgm Number Of Leases
NumberOfLeases
2 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
771099 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309651 shares
CY2023Q2 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2022Q4 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2023Q2 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
434000 usd
CY2022Q4 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
290000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
561000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
93057 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
184577 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
108612 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
216346 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
612000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
765000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
330000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
282000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
180000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
370000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
106000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
656000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
612000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
84000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
81000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000 usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
2000 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
19000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
93000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
109000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
168000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
166000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
0 usd
bsgm Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-53000 usd
us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
0 usd
CY2023Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
3000 usd
CY2023Q2 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
171000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
53000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
104000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
13000 usd
CY2023Q2 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
3000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
173000 usd
CY2023Q2 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
2000 usd
CY2023Q2 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
171000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3376231 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10172823 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P6Y
us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
43601 shares
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
841000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
646000 usd
CY2023Q2 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
37000 usd
CY2022Q4 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
33000 usd
CY2023Q2 bsgm Accrued Consulting Current
AccruedConsultingCurrent
569000 usd
CY2022Q4 bsgm Accrued Consulting Current
AccruedConsultingCurrent
546000 usd
CY2023Q2 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
315000 usd
CY2022Q4 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
625000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2023Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
234000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
256000 usd
CY2023Q2 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
244000 usd
CY2022Q4 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
220000 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
638000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
513000 usd
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
13000 usd
CY2022Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
13000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2906000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022 bsgm Deemed Preferred Stock Dividend
DeemedPreferredStockDividend
209682 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73457375 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
2370000 shares
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1060740 usd
bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
471085 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.8692
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4555484 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.49
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
3000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1217500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.34
bsgm Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
463333 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.6
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309651 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
244770
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3376231 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.7
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
184934 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y8M12D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4217111 shares
CY2022Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
1.89
CY2022 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P4Y3M18D
CY2022Q4 bsgm Class Of Warrant Or Rights Outstanding Intrinsic Value
ClassOfWarrantOrRightsOutstandingIntrinsicValue
3960000 usd
bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
6016688 shares
bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
0.9
bsgm Warrants Granted Weighted Average Remaining Contractual Term
WarrantsGrantedWeightedAverageRemainingContractualTerm
P5Y2M12D
bsgm Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
-60976 shares
bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised
0.41
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10172823 shares
CY2023Q2 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
1.31
bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P4Y7M6D
CY2023Q2 bsgm Class Of Warrant Or Rights Outstanding Intrinsic Value
ClassOfWarrantOrRightsOutstandingIntrinsicValue
0 usd
CY2023Q2 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding
10172823 shares
CY2023Q2 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding
1.31
bsgm Warrants Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P4Y7M6D
CY2023Q2 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding Intrinsic Value
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue
3391187000 usd
CY2023Q2 bsgm Class Of Warrant Or Rights Exercisable
ClassOfWarrantOrRightsExercisable
4156135 shares
CY2023Q2 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
1.91
bsgm Warrants Exercisable Weighted Average Remaining Contractual Term
WarrantsExercisableWeightedAverageRemainingContractualTerm
P3Y9M18D
CY2023Q2 bsgm Class Of Warrant Or Rights Exercisable Intrinsic Value
ClassOfWarrantOrRightsExercisableIntrinsicValue
1195924000 usd
CY2023Q1 us-gaap Share Price
SharePrice
1.25
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
260000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
vesting quarterly over one year
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
301600 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
101822 usd
us-gaap Share Based Compensation
ShareBasedCompensation
206526 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
71187 usd
us-gaap Share Based Compensation
ShareBasedCompensation
141541 usd
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2650071 shares
CY2023Q2 bsgm Subsidiary Or Equity Method Investee Minority Interest In Income Loss Of Subsidiary
SubsidiaryOrEquityMethodInvesteeMinorityInterestInIncomeLossOfSubsidiary
137000 usd
CY2023Q2 bsgm Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.27 pure
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-37000 usd
CY2022Q2 bsgm Subsidiary Or Equity Method Investee Minority Interest In Income Loss Of Subsidiary
SubsidiaryOrEquityMethodInvesteeMinorityInterestInIncomeLossOfSubsidiary
-136000 usd
CY2022Q2 bsgm Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.316 pure
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
43000 usd
bsgm Subsidiary Or Equity Method Investee Minority Interest In Income Loss Of Subsidiary
SubsidiaryOrEquityMethodInvesteeMinorityInterestInIncomeLossOfSubsidiary
299000 usd
bsgm Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.29 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87000 usd
bsgm Subsidiary Or Equity Method Investee Minority Interest In Income Loss Of Subsidiary
SubsidiaryOrEquityMethodInvesteeMinorityInterestInIncomeLossOfSubsidiary
186000 usd
bsgm Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.317 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-59000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Issuance Of Equity By Subsidiary To Noncontrolling Interests
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesIssuanceOfEquityBySubsidiaryToNoncontrollingInterests
188000 usd
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
9000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-87000 usd
CY2023Q2 us-gaap Minority Interest
MinorityInterest
89000 usd
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
63818 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
129737 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
67888 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
135528 usd
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2966181 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
8000 usd
us-gaap Revenues
Revenues
5000 usd
us-gaap Revenues
Revenues
16000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
10908000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5724000 usd
us-gaap Operating Expenses
OperatingExpenses
18299000 usd
us-gaap Operating Expenses
OperatingExpenses
13797000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10908000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5716000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18294000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13781000 usd
CY2023Q2 us-gaap Assets
Assets
4050000 usd
CY2022Q4 us-gaap Assets
Assets
4110000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
120000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001530766

Files In Submission

Name View Source Status
0001185185-23-000845-index-headers.html Edgar Link pending
0001185185-23-000845-index.html Edgar Link pending
0001185185-23-000845.txt Edgar Link pending
0001185185-23-000845-xbrl.zip Edgar Link pending
biosig20230630_10q.htm Edgar Link pending
bsgm-20230630.xsd Edgar Link pending
ex_554840.htm Edgar Link pending
ex_554841.htm Edgar Link pending
ex_554842.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
bsgm-20230630_cal.xml Edgar Link unprocessable
bsgm-20230630_def.xml Edgar Link unprocessable
bsgm-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bsgm-20230630_pre.xml Edgar Link unprocessable
biosig20230630_10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending